Monopar Therapeutics Inc. Share Price
MNPRMonopar Therapeutics Inc. Stock Performance
Open $107.02 | Prev. Close $108.32 | Circuit Range N/A |
Day Range $104.89 - $110.42 | Year Range $29.22 - $111.36 | Volume 11,221 |
Average Traded $108.41 |
Monopar Therapeutics Inc. Share Price Chart
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Monopar Therapeutics Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
17-Jul-26 | $107.02 | $110.30 | +1.83% |
16-Jul-26 | $107.00 | $108.32 | -0.88% |
15-Jul-26 | $100.25 | $109.28 | +9.99% |
14-Jul-26 | $100.71 | $99.35 | -3.21% |
13-Jul-26 | $105.40 | $102.65 | -3.45% |
10-Jul-26 | $101.35 | $106.31 | +2.14% |
09-Jul-26 | $98.85 | $104.09 | +5.10% |